Used primarily in the treatment of osteoporosis, Paget's disease of bone, and bone metastases, this compound helps reduce bone resorption by inhibiting osteoclast activity. It is effective in increasing bone mineral density and reducing fracture risk in patients with osteoporosis. In oncology, it prevents skeletal-related events in patients with cancers that have spread to bone, such as multiple myeloma and advanced breast cancer. The compound is also used to treat hypercalcemia of malignancy, helping normalize elevated calcium levels in blood. Administered intravenously, it offers a potent option for managing complex bone disorders with a relatively infrequent dosing schedule.